🇺🇸 FDA
Pipeline program

Sonelokimab

M1095-HS-302

Phase 3 small_molecule active

Quick answer

Sonelokimab for Hidradenitis Suppurativa is a Phase 3 program (small_molecule) at MoonLake Immunotherapeutics with 4 ClinicalTrials.gov record(s).

Program details

Company
MoonLake Immunotherapeutics
Indication
Hidradenitis Suppurativa
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials